Susoctocog Alfa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Susoctocog Alfa |
| DrugBank ID | DB11606 |
| Brand Names (EU) | Obizur |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.94% |
Approved Indication (EMA)
Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 99.94% | DL |
| 2 | pseudo-von Willebrand disease | 99.93% | DL |
| 3 | Glanzmann thrombasthenia | 99.88% | DL |
| 4 | hemophilia | 99.74% | DL |
| 5 | acquired coagulation factor deficiency | 99.64% | DL |
| 6 | Scott syndrome | 99.60% | DL |
| 7 | acquired hemophilia | 99.19% | DL |
| 8 | bleeding diathesis due to a collagen receptor defect | 99.17% | DL |
| 9 | hemorrhagic disorder due to a constitutional thrombocytopenia | 99.17% | DL |
| 10 | congenital factor XIII deficiency | 99.15% | DL |
| 11 | adenosine deaminase deficiency | 99.04% | DL |
| 12 | factor XIII, A subunit, deficiency | 98.84% | DL |
| 13 | prothrombin deficiency | 98.69% | DL |
| 14 | congenital factor VII deficiency | 98.38% | DL |
| 15 | reticular dysgenesis | 98.37% | DL |
| 16 | hemorrhagic disorder due to a platelet anomaly | 98.30% | DL |
| 17 | severe combined immunodeficiency due to LCK deficiency | 98.20% | DL |
| 18 | platelet-type bleeding disorder | 98.09% | DL |
| 19 | fetal and neonatal alloimmune thrombocytopenia | 97.73% | DL |
| 20 | hemophilia A with vascular abnormality | 97.46% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.